Inclusion Criteria:  Males and females between 18 years and 55 years of age. Must be in good general health as confirmed by a medical history and physical exam. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and on the day of each study vaccination and must not be breast-feeding.Those that have sexual relationships with men are required to use one of the following methods of contraception from enrollment in study until 30 days after last injection: hormonal (e.g. oral, transdermal, intravaginal, implant, or injection); double barrier (i.e., condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6 months minimum); or abstinence; bilateral tubal ligation (if no conception post-procedure); tubal occlusion; or bilateral salpingectomy. These precautions are necessary due to unknown effects that Vacina RNA MCTI CIMATEC HDT might cause in a fetus or newborn infant. Women are considered non-child-bearing potential if they are post-menopausal (defined as at least 12 months spontaneous amenorrhea and confirmed with FSH > 40 mIU/ml) or have had documented hysterectomy and/or oophorectomy and non-sterile men who agree to use proper contraception with their partner during and up to 30 days after the last injection of study vaccine; The following screening laboratory values must be within the normal ranges or not clinically significant as determined by the Investigator and approved by the Medical Monitor: sodium, potassium, BUN, ALT, AST, total bilirubin, alkaline phosphatase, creatinine, fasting glucose, total WBC count, hemoglobin, and platelet count. Abnormal results may be repeated once for confirmation at Investigator discretion. The following serology tests must be negative: SARS-CoV-2 antibody, HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. Negative test for recreational drugs and alcohol per Clinical Research Unit standards. Normal or not clinically significant urinalysis as determined by the study clinician or designee. Abnormal results may be repeated at Investigator discretion. Normal blood count within 10 days before the administration of the first dose of the VACINA RNA MCTI CIMATEC HDT vaccine. Must be capable of completing the Adverse Event Mnemonic Questionnaire. Must have negative RT-PCR test for SARS-CoV-2 24 to 48 h before administration of study vaccine and absence of signs and symptoms compatible with COVID-19 (eg, fever, cough, shortness of breath, chills,etc.);  Must give informed consent, be able and willing to make all evaluation visits, be reachable by telephone or personal contact by the study site personnel, and have a permanent address.  -  Exclusion Criteria:  Participation in another experimental protocol and/or receipt of any investigational products within the past 3 months prior to Screening. Individuals infected with SARS-CoV-2 confirmed by RT-PCR or previously exposed to SARS-CoV-2 infection confirmed by detection of total IgG antibodies by ELISA; Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as prednisone; high dose inhaled steroids) or cytotoxic therapies (e.g., chemotherapy drugs or radiation) in the past 6 months prior to Screening History of blood, plasma or immunogloblulin transfusion within past 3 months prior to screening. Donation of blood products (platelets, whole blood, plasma, etc.) in the last month before screening (1 month before screening) . Received any vaccinations in the last month before screening or have any immunizations planned during the study, with the exception of seasonal influenza vaccine, which can be given after 30 days after the second injection of the study. Participants who have been immunized with any vaccine for SARS-CoV-2 (or other COVID-19 prevention treatment) at any time; History of autoimmune disease or other causes of immunosuppressive states. History of any other acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders, uncontrolled hypertension), or use of medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine. Skin rash, tattoos, or any other dermatological condition that could adversely affect the vaccine injection site or interfere with its evaluation. BMI ≥ 32. Hypertension (systolic > 150 or diastolic > 95). History of significant psychiatric illness with current use of medication. Known or suspected alcohol or drug abuse within the past 6 months prior to screening. Chronic tobacco user (> 20 pack years). Individuals with a history of previous anaphylaxis or severe allergic reaction to unknown vaccines or allergens. Individuals unlikely to cooperate with the requirements of the study protocol.